https://old.international-biopharma.com/pfizer-pares-back-early-stage-research-in-rare-disease-cancer/ 2023-01-09T10:03:52+00:00 https://old.international-biopharma.com/fate-two-other-cell-therapy-biotechs-lay-off-staff-restructure-research/ 2023-01-09T10:02:45+00:00 https://old.international-biopharma.com/ensoma-buys-a-startup-to-advance-in-vivo-cell-therapy-work/ 2023-01-09T09:29:03+00:00 https://old.international-biopharma.com/jjs-next-myeloma-drug-argenxs-second-act-and-a-new-question-for-bluebird-3-ash-takeaways/ 2022-12-19T10:17:27+00:00 https://old.international-biopharma.com/at-ash-regeneron-plays-catch-up-with-its-next-cancer-drugs/ 2022-12-19T10:10:32+00:00 https://old.international-biopharma.com/gene-therapy-approval-won-bluebird-takes-on-next-challenge-selling-it/ 2022-12-19T10:07:47+00:00 https://old.international-biopharma.com/lilly-lays-out-ambitious-plans-for-2023/ 2022-12-19T10:06:12+00:00 https://old.international-biopharma.com/importance-of-lyobeads-and-using-the-micropress-to-determine-quality-metrics/ 2022-12-12T16:07:19+00:00 https://old.international-biopharma.com/how-to-keep-breathing-the-future-of-inhaled-medication-testing/ 2022-12-12T16:06:51+00:00 https://old.international-biopharma.com/automated-sterile-manufacturing-and-packaging-solutions-aiding-speed-to-patient/ 2022-12-12T16:06:18+00:00 https://old.international-biopharma.com/new-models-of-innovation-in-laboratory-operations/ 2022-12-12T16:05:44+00:00 https://old.international-biopharma.com/adcs-from-lab-to-clinical-development/ 2022-12-12T16:05:07+00:00 https://old.international-biopharma.com/pro-electrophiles-a-previously-overlooked-class-of-protein-reactive-extractables/ 2022-12-12T16:04:32+00:00 https://old.international-biopharma.com/why-regulatory-convergence-is-key-to-global-development-of-cell-and-gene-therapies/ 2022-12-12T16:04:01+00:00 https://old.international-biopharma.com/the-evolving-landscape-of-academic-research-integrity/ 2022-12-12T16:03:26+00:00 https://old.international-biopharma.com/advancing-toward-proactive-quality-management/ 2022-12-12T16:02:52+00:00 https://old.international-biopharma.com/pharvaris-pushing-through-trial-pause-sees-shares-surge-with-new-study-results/ 2022-12-12T10:00:22+00:00 https://old.international-biopharma.com/biotech-layoffs-claim-more-jobs-at-sensei-instil-therapeuticsmd/ 2022-12-12T09:59:08+00:00 https://old.international-biopharma.com/gilead-buys-into-multiple-myeloma-cell-therapy-with-arcellx-deal/ 2022-12-12T09:57:36+00:00 https://old.international-biopharma.com/vertex-invests-in-a-rare-disease-drug-and-its-developer/ 2022-12-12T09:56:45+00:00 https://old.international-biopharma.com/novartis-gets-second-trial-win-for-blockbuster-hopeful/ 2022-12-12T09:55:59+00:00 https://old.international-biopharma.com/gene-therapy-approvals-bring-validation-as-field-closes-year-on-high/ 2022-12-12T09:55:13+00:00 https://old.international-biopharma.com/cphi-frankfurt-returns-to-pre-pandemic-strength-as-pharma-industry-booms-again/ 2022-12-09T13:35:21+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/12/CPHI-Frankfurt.jpg https://old.international-biopharma.com/highlights-from-the-fiped-global-education-report/ 2022-12-07T16:11:13+00:00 https://old.international-biopharma.com/curricula-then-and-now-an-environmental-scan-and-recommendations/ 2022-12-07T16:09:27+00:00 https://old.international-biopharma.com/jjs-duato-to-replace-departing-gorsky-as-board-chair/ 2022-12-05T09:43:09+00:00 https://old.international-biopharma.com/fda-approves-first-microbiota-based-treatment/ 2022-12-05T09:41:34+00:00 https://old.international-biopharma.com/rigel-wins-us-approval-of-rival-drug-to-servier-leukemia-treatment/ 2022-12-05T09:40:40+00:00 https://old.international-biopharma.com/fda-grants-speedy-review-to-sareptas-duchenne-gene-therapy/ 2022-12-05T09:38:21+00:00 https://old.international-biopharma.com/novo-nordisk-to-boost-drug-manufacturing-in-denmark/ 2022-11-28T09:37:38+00:00 https://old.international-biopharma.com/fda-approves-first-gene-therapy-for-hemophilia-b/ 2022-11-28T09:36:27+00:00 https://old.international-biopharma.com/teva-taps-sandoz-veteran-to-take-over-ceo-post-from-schultz/ 2022-11-28T09:34:51+00:00 https://old.international-biopharma.com/merck-to-buy-blood-cancer-biotech-imago-for-1-35b/ 2022-11-28T09:33:55+00:00 https://old.international-biopharma.com/gsk-to-pull-blood-cancer-drug-from-us-market-after-study-failure/ 2022-11-28T09:32:26+00:00 https://old.international-biopharma.com/novo-nordisk-pharmatech-a-s/ 2022-11-25T11:35:29+00:00 https://old.international-biopharma.com/former-rubius-ceo-to-lead-buzzy-flagship-startup/ 2022-11-21T09:12:55+00:00 https://old.international-biopharma.com/fda-panel-votes-in-favor-of-ardelyxs-once-rejected-kidney-disease-drug/ 2022-11-21T09:11:45+00:00 https://old.international-biopharma.com/biotechs-reveal-layoffs-research-revamps-in-third-quarter-earnings/ 2022-11-21T09:10:45+00:00 https://old.international-biopharma.com/first-of-its-kind-type-1-diabetes-drug-wins-fda-approval/ 2022-11-21T09:09:40+00:00 https://old.international-biopharma.com/under-fda-pressure-gsk-limits-use-of-ovarian-cancer-drug/ 2022-11-14T09:26:06+00:00 https://old.international-biopharma.com/fda-declines-to-review-brainstorms-als-therapy/ 2022-11-14T09:25:07+00:00 https://old.international-biopharma.com/biogen-names-former-sanofi-head-viehbacher-to-replace-vounatsos-as-ceo/ 2022-11-14T09:24:02+00:00 https://old.international-biopharma.com/seagen-picks-novartis-flagship-veteran-epstein-as-new-ceo/ 2022-11-14T09:22:41+00:00 https://old.international-biopharma.com/early-data-hint-at-benefit-for-amgens-obesity-drug/ 2022-11-14T09:21:01+00:00 https://old.international-biopharma.com/cphi-frankfurt-2022-global-pharma-confidence-hits-record-high-in-the-annual-cphi-pharma-index/ 2022-11-11T11:53:26+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/11/Screenshot-2022-11-11-at-11.50.28.png https://old.international-biopharma.com/wp-content/uploads/2022/11/2.png https://old.international-biopharma.com/wp-content/uploads/2022/11/3.png https://old.international-biopharma.com/cphi-excellence-in-pharma-award-winners-2022/ 2022-11-11T11:49:03+00:00 https://old.international-biopharma.com/biogenes-superior-services-since-1992/ 2022-11-07T11:48:03+00:00 https://old.international-biopharma.com/rubius-replaces-ceo-as-it-cuts-more-jobs-and-considers-a-sale/ 2022-11-07T09:51:31+00:00 https://old.international-biopharma.com/string-of-gene-therapy-deals-spurs-cautious-optimism-on-wall-street/ 2022-11-07T09:25:14+00:00 https://old.international-biopharma.com/galapagos-to-cut-200-jobs-amid-research-revamp/ 2022-11-07T09:23:55+00:00 https://old.international-biopharma.com/bispecific-cancer-drugs-and-gene-therapy-advances-what-to-watch-at-next-months-ash-meeting/ 2022-11-07T09:23:07+00:00 https://old.international-biopharma.com/artiva-cancels-ipo-plans-and-cuts-a-deal-with-affimed/ 2022-11-07T09:21:04+00:00 https://old.international-biopharma.com/media-information-2021/ 2022-10-28T11:05:25+00:00 https://old.international-biopharma.com/join-medicilon-at-the-cphi-world-wide-2022/ 2022-10-24T16:03:33+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/10/MEDICILON-1.png https://old.international-biopharma.com/pci-pharma-services/ 2022-10-24T10:35:38+00:00 https://old.international-biopharma.com/pfizer-planning-steep-price-hike-for-covid-19-vaccine/ 2022-10-24T08:58:14+00:00 https://old.international-biopharma.com/prime-medicine-raises-175m-in-one-of-the-years-largest-biotech-ipos/ 2022-10-24T08:56:48+00:00 https://old.international-biopharma.com/fda-advisers-back-withdrawal-of-controversial-drug-for-preterm-birth/ 2022-10-24T08:47:00+00:00 https://old.international-biopharma.com/speedy-fda-approvals-in-focus-as-agency-weighs-withdrawal-of-preterm-birth-drug/ 2022-10-24T08:45:06+00:00 https://old.international-biopharma.com/gsk-sets-high-bar-with-trial-results-for-rsv-vaccine/ 2022-10-17T14:40:13+00:00 https://old.international-biopharma.com/relmada-shares-collapse-after-fast-acting-depression-drug-fails-first-test/ 2022-10-17T14:36:42+00:00 https://old.international-biopharma.com/we-have-to-find-a-way-fda-seeks-solutions-to-aid-bespoke-gene-therapy/ 2022-10-17T14:33:58+00:00 https://old.international-biopharma.com/enliven-to-enter-public-markets-through-reverse-merger-with-imara/ 2022-10-17T14:31:42+00:00 https://old.international-biopharma.com/preparing-biopharmaceutical-downstream-processing-supply-chains-for-resiliency-post-pandemic/ 2022-10-12T12:29:06+00:00 https://old.international-biopharma.com/live-cell-transport-the-new-way-of-transportation/ 2022-10-12T12:28:48+00:00 https://old.international-biopharma.com/how-scalable-manufacture-will-enable-progress-for-lentiviral-therapies/ 2022-10-12T12:28:29+00:00 https://old.international-biopharma.com/advancing-cardiac-drug-discovery-with-human-induced-pluripotent-stem-cell-technology/ 2022-10-12T12:28:00+00:00 https://old.international-biopharma.com/manufacturing-of-biological-tissues-standardisation-and-automation/ 2022-10-12T12:27:39+00:00 https://old.international-biopharma.com/developing-stable-lentiviral-cell-lines/ 2022-10-12T12:27:22+00:00 https://old.international-biopharma.com/working-in-tandem-formulation-science-and-drug-delivery-device-design/ 2022-10-12T12:27:04+00:00 https://old.international-biopharma.com/accessing-greater-dimensions-of-biological-understanding-through-lc-ms-proteomics/ 2022-10-12T12:26:47+00:00 https://old.international-biopharma.com/how-to-hire-a-translation-agency/ 2022-10-12T12:26:21+00:00 https://old.international-biopharma.com/understanding-and-overcoming-the-challenges-of-flow-cytometry/ 2022-10-12T12:26:03+00:00 https://old.international-biopharma.com/adapting-to-an-everchanging-regulatory-landscape/ 2022-10-12T12:25:45+00:00 https://old.international-biopharma.com/what-is-a-blockchain-why-its-perfect-for-healthcare-applications/ 2022-10-12T12:25:25+00:00 https://old.international-biopharma.com/gerresheimer-innovating-for-a-better-life/ 2022-10-12T12:25:06+00:00 https://old.international-biopharma.com/biohaven-starts-life-as-new-company-following-pfizer-buyout/ 2022-10-07T08:16:09+00:00 https://old.international-biopharma.com/sanofi-takes-a-chance-on-proventions-diabetes-drug-with-marketing-deal/ 2022-10-07T08:15:17+00:00 https://old.international-biopharma.com/takeda-to-stop-making-parathyroid-drug-natpara-in-2024-after-production-challenges/ 2022-10-07T08:14:17+00:00 https://old.international-biopharma.com/a-versant-backed-biotech-emerges-to-take-on-overlooked-cancer-targets/ 2022-10-07T08:13:16+00:00 https://old.international-biopharma.com/cphi-pharma-award-finalists-announced-at-connect-to-frankfurt/ 2022-10-03T14:15:21+00:00 https://old.international-biopharma.com/with-little-data-to-go-on-experts-question-how-useful-eisai-biogens-new-alzheimers-drug-will-be/ 2022-10-03T08:25:40+00:00 https://old.international-biopharma.com/sarepta-asks-fda-to-approve-first-gene-therapy-for-duchenne-muscular-dystrophy/ 2022-10-03T08:09:09+00:00 https://old.international-biopharma.com/biogen-eisai-data-raises-hope-for-other-experimental-alzheimers-drugs/ 2022-10-03T08:08:19+00:00 https://old.international-biopharma.com/in-surprise-result-alzheimers-drug-from-eisai-biogen-shows-benefit-in-large-trial/ 2022-10-03T08:07:42+00:00 https://old.international-biopharma.com/vertex-given-green-light-to-seek-us-approval-of-crispr-based-therapy/ 2022-10-03T08:06:26+00:00 https://old.international-biopharma.com/als-drug-approved-by-fda-in-closely-watched-decision-marking-win-for-patients-developer-2/ 2022-10-03T08:05:41+00:00 https://old.international-biopharma.com/als-drug-approved-by-fda-in-closely-watched-decision-marking-win-for-patients-developer/ 2022-10-03T08:03:33+00:00 https://old.international-biopharma.com/fda-advisers-back-microbiota-based-treatment-for-gut-infection/ 2022-09-26T08:03:43+00:00 https://old.international-biopharma.com/fda-user-fee-package-to-be-included-in-bill-to-fund-government-avoid-shutdown-senators-say/ 2022-09-26T08:03:01+00:00 https://old.international-biopharma.com/novartis-warns-of-sales-hit-after-federal-court-turns-back-patent-appeal/ 2022-09-26T08:02:23+00:00 https://old.international-biopharma.com/back-to-back-gene-therapy-approvals-give-bluebird-shot-at-survival/ 2022-09-26T08:01:17+00:00 https://old.international-biopharma.com/astrazeneca-gives-up-on-ionis-rna-drug-for-heart-disease/ 2022-09-26T08:00:06+00:00 https://old.international-biopharma.com/precision-for-medicine-2/ 2022-09-12T15:04:41+00:00 https://old.international-biopharma.com/alnylam-details-anticipated-results-from-heart-disease-drug-trial/ 2022-09-09T12:38:26+00:00 https://old.international-biopharma.com/regeneron-answers-rivals-with-data-for-new-version-of-top-selling-eye-drug/ 2022-09-09T12:36:51+00:00 https://old.international-biopharma.com/gilead-says-its-breast-cancer-drug-helped-patients-live-longer-in-study/ 2022-09-09T12:35:45+00:00 https://old.international-biopharma.com/relay-impresses-with-early-study-data-for-targeted-cancer-drug/ 2022-09-09T12:34:30+00:00 https://old.international-biopharma.com/novartis-bradner-steps-down-as-research-head-amid-company-shake-up/ 2022-09-04T20:46:00+00:00 https://old.international-biopharma.com/with-rare-acquisition-novo-nordisk-makes-1b-bet-on-sickle-cell-disease-drug/ 2022-09-04T20:43:31+00:00 https://old.international-biopharma.com/bristol-myers-bayer-study-results-seed-doubt-about-an-emerging-group-of-blood-thinners/ 2022-09-04T20:42:16+00:00 https://old.international-biopharma.com/judge-rules-in-favor-of-illumina-countering-ftc-concerns-over-grail-merger/ 2022-09-04T20:30:28+00:00 https://old.international-biopharma.com/finch-to-lay-off-37-of-staff-after-takeda-ends-microbiome-drug-deal/ 2022-09-04T20:29:13+00:00 https://old.international-biopharma.com/with-2-8m-gene-therapy-bluebird-sets-new-bar-for-us-drug-pricing/ 2022-08-22T08:33:52+00:00 https://old.international-biopharma.com/merck-pays-startup-orna-150m-as-circular-rna-attracts-industry-interest/ 2022-08-22T08:24:25+00:00 https://old.international-biopharma.com/ventyx-touts-early-data-for-potential-rival-to-bristol-myers-psoriasis-drug/ 2022-08-22T08:22:09+00:00 https://old.international-biopharma.com/bluebird-gene-therapy-approved-by-fda-for-rare-blood-disease/ 2022-08-22T08:19:36+00:00 https://old.international-biopharma.com/bluejay-raises-41m-to-bring-hepatitis-b-drugs-to-clinical-testing/ 2022-08-22T08:15:11+00:00 https://old.international-biopharma.com/axsome-rebounds-to-win-fda-approval-of-depression-drug/ 2022-08-22T08:12:22+00:00 https://old.international-biopharma.com/cellbox-solutions/ 2022-08-19T14:39:50+00:00 https://old.international-biopharma.com/gerresheimer/ 2022-08-16T15:06:13+00:00 https://old.international-biopharma.com/byondis/ 2022-08-16T15:00:01+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/08/20201209_Byondis_3085-scaled.jpg https://old.international-biopharma.com/wp-content/uploads/2022/08/20201209_Byondis_5573-scaled.jpg https://old.international-biopharma.com/wp-content/uploads/2022/08/20201209_Byondis_3685-.jpg https://old.international-biopharma.com/amgens-low-tax-rates-draw-attention-of-top-democratic-senator/ 2022-08-15T08:33:12+00:00 https://old.international-biopharma.com/gsk-pfizer-sanofi-shares-drop-amid-zantac-litigation-concerns/ 2022-08-15T08:32:14+00:00 https://old.international-biopharma.com/bristol-myers-claims-success-in-study-testing-earlier-car-t-use-in-multiple-myeloma/ 2022-08-15T08:31:10+00:00 https://old.international-biopharma.com/seagen-loses-arbitration-case-to-daiichi-sankyo-over-cancer-drug-technology/ 2022-08-15T08:29:50+00:00 https://old.international-biopharma.com/new-enhertu-approval-adds-to-growing-role-of-well-known-cancer-target/ 2022-08-15T08:28:47+00:00 https://old.international-biopharma.com/vectorbuilder/ 2022-08-08T09:24:44+00:00 https://old.international-biopharma.com/fda-approves-astrazeneca-daiichi-drug-in-breast-cancer-first/ 2022-08-08T07:54:49+00:00 https://old.international-biopharma.com/how-a-small-uk-biotech-ended-up-in-gileads-hands/ 2022-08-08T07:53:48+00:00 https://old.international-biopharma.com/lilly-takes-long-view-on-alzheimers-drug-as-fda-starts-expedited-review/ 2022-08-08T07:49:27+00:00 https://old.international-biopharma.com/acadia-turned-back-by-fda-on-second-attempt-to-get-psychosis-drug-approved/ 2022-08-08T07:48:10+00:00 https://old.international-biopharma.com/amgen-bets-almost-4b-on-a-biotech-and-its-inflammation-drugs/ 2022-08-08T07:47:28+00:00 https://old.international-biopharma.com/sarepta-to-ask-fda-for-accelerated-approval-of-duchenne-gene-therapy/ 2022-07-31T21:45:20+00:00 https://old.international-biopharma.com/us-secures-updated-covid-boosters-in-1-7b-deal-with-moderna/ 2022-07-31T21:42:36+00:00 https://old.international-biopharma.com/alnylam-reveals-longer-wait-for-anticipated-drug-trial-results/ 2022-07-31T21:41:40+00:00 https://old.international-biopharma.com/pfizer-sales-of-covid-19-vaccine-pill-beat-forecasts-as-company-prepares-for-future-waves/ 2022-07-31T21:40:45+00:00 https://old.international-biopharma.com/abbvie-cancer-drug-sales-fall-as-astrazeneca-competitor-gains-ground/ 2022-07-31T21:38:05+00:00 https://old.international-biopharma.com/fda-signs-off-on-bavarian-nordic-plant-allowing-distribution-of-monkeypox-vaccine-doses/ 2022-07-31T21:37:22+00:00 https://old.international-biopharma.com/european-regulator-recommends-bavarian-nordics-vaccine-for-monkeypox/ 2022-07-24T12:51:39+00:00 https://old.international-biopharma.com/roche-ceo-schwan-who-guided-company-as-cancer-drug-powerhouse-to-step-down-next-year/ 2022-07-24T12:50:08+00:00 https://old.international-biopharma.com/vertex-verve-team-up-to-develop-a-gene-editing-drug-for-liver-disease/ 2022-07-24T12:48:12+00:00 https://old.international-biopharma.com/drug-deals-launches-in-focus-as-pharma-earnings-begin/ 2022-07-24T12:47:04+00:00 https://old.international-biopharma.com/after-a-lengthy-drought-could-biotech-ma-be-on-the-upswing-2/ 2022-07-24T12:44:32+00:00 https://old.international-biopharma.com/with-aduhelm-sidelined-wall-street-turns-to-biogens-next-alzheimers-drug/ 2022-07-24T12:43:38+00:00 https://old.international-biopharma.com/oxgene/ 2022-07-22T13:03:34+00:00 https://old.international-biopharma.com/richter-helm/ 2022-07-22T12:59:58+00:00 https://old.international-biopharma.com/biopharma-group/ 2022-07-22T12:52:16+00:00 https://old.international-biopharma.com/almac-group/ 2022-07-22T12:47:27+00:00 https://old.international-biopharma.com/tower-cold-chain-secures-further-investment-to-supercharge-its-success/ 2022-07-21T09:27:40+00:00 https://old.international-biopharma.com/wp-content/uploads/2022/07/Tower-Cold-Chain-Product-Range.jpg https://old.international-biopharma.com/wp-content/uploads/2022/07/Robust-Reliable-Reusable-temperature-controlled-protection-for-pharmaceuticals.jpg https://old.international-biopharma.com/wp-content/uploads/2022/07/Niall-Balfour-CEO-Tower-Cold-Chain.jpg https://old.international-biopharma.com/fda-clears-novavaxs-covid-19-vaccine-as-4th-option-in-us/ 2022-07-15T07:59:13+00:00 https://old.international-biopharma.com/royalty-pharma-buys-rights-to-top-selling-gsk-drug-in-pair-of-deals/ 2022-07-15T07:58:33+00:00 https://old.international-biopharma.com/agios-ceo-to-step-down-handing-role-to-veteran-in-rare-disease-drug-sales/ 2022-07-15T07:54:35+00:00 https://old.international-biopharma.com/novartis-beigene-cancer-drug-faces-delay-as-fda-puts-off-approval-decision/ 2022-07-15T07:53:46+00:00 https://old.international-biopharma.com/cytomx-lays-off-staff-joining-growing-list-of-biotechs-restructuring/ 2022-07-15T07:52:50+00:00 https://old.international-biopharma.com/atara-shares-sink-after-update-on-multiple-sclerosis-trial/ 2022-07-15T07:52:10+00:00 https://old.international-biopharma.com/as-merck-closes-in-on-seagen-the-ftc-nears-a-key-test-on-pharma-deals/ 2022-07-11T08:12:57+00:00 https://old.international-biopharma.com/abbvie-dials-back-partnership-on-experimental-alzheimers-drug/ 2022-07-11T08:11:51+00:00 https://old.international-biopharma.com/radius-fending-off-activists-outlines-pitch-for-890-million-buyout/ 2022-07-11T08:10:34+00:00 https://old.international-biopharma.com/new-analysis-encourages-intercept-to-refile-nash-drug-for-approval/ 2022-07-11T08:09:46+00:00 https://old.international-biopharma.com/biotech-ma-is-picking-back-up-here-are-the-latest-deals-2/ 2022-07-11T08:08:56+00:00 https://old.international-biopharma.com/after-a-lengthy-drought-could-biotech-ma-be-on-the-upswing/ 2022-07-11T08:08:20+00:00 https://old.international-biopharma.com/fda-halts-tests-of-sanofi-drug-acquired-in-3-7b-buyout-due-to-side-effects/ 2022-07-01T12:38:31+00:00 https://old.international-biopharma.com/novartis-details-plans-to-lay-off-up-to-8000-amid-sweeping-restructuring/ 2022-07-01T12:37:45+00:00 https://old.international-biopharma.com/blueprint-secures-access-to-more-than-1b-in-funding-through-two-new-deals/ 2022-07-01T12:36:47+00:00 https://old.international-biopharma.com/astrazeneca-chasing-immunotherapy-rivals-claims-study-success-in-early-lung-cancer/ 2022-07-01T12:35:48+00:00 https://old.international-biopharma.com/biotech-ma-is-picking-back-up-here-are-the-latest-deals/ 2022-07-01T12:34:45+00:00 https://old.international-biopharma.com/crunching-the-numbers-on-the-first-half-drought-for-biotech-ipos/ 2022-07-01T12:34:09+00:00 https://old.international-biopharma.com/meeting-growing-demand-fill-finish-and-cold-chain-strategies-and-tactics/ 2022-06-28T12:47:52+00:00 https://old.international-biopharma.com/cancer-vaccines-getting-personal/ 2022-06-28T12:47:19+00:00 https://old.international-biopharma.com/optimisation-of-a-quality-control-method-for-identity-purity-and-quantity-for-oligonucleotide-therapeutics/ 2022-06-28T12:46:45+00:00 https://old.international-biopharma.com/how-to-speed-up-vaccine-development-and-production-with-genetic-vaccine-technology/ 2022-06-28T12:46:12+00:00 https://old.international-biopharma.com/single-use-technology-in-cell-and-gene-therapies-transferable-lessons-from-the-bioprocessing-industry/ 2022-06-28T12:45:47+00:00 https://old.international-biopharma.com/secrets-to-packaging-ultra-low-temperature-products-what-every-manufacturer-should-know/ 2022-06-28T12:45:20+00:00 https://old.international-biopharma.com/human-factors-studies-testing-a-platform-device-during-the-pandemic/ 2022-06-28T12:44:51+00:00 https://old.international-biopharma.com/why-it-is-time-to-think-different-about-nasal-delivery-of-biologics/ 2022-06-28T12:44:24+00:00 https://old.international-biopharma.com/the-potential-of-ims-ms-for-clinical-applications-of-untargeted-metabolomics/ 2022-06-28T12:43:52+00:00 https://old.international-biopharma.com/overcoming-the-challenges-of-large-scale-plasmid-production/ 2022-06-28T12:43:26+00:00 https://old.international-biopharma.com/biotechs-start-as-you-mean-to-go-on-free-from-the-workaround-data-management-practices-that-beset-big-pharma/ 2022-06-28T12:42:59+00:00 https://old.international-biopharma.com/supplement-sector-should-carve-its-own-path-toward-innovation/ 2022-06-28T12:42:02+00:00 https://old.international-biopharma.com/cost-savings-discover-four-benefits-of-the-used-equipment-market-for-your-company/ 2022-06-28T12:41:35+00:00 https://old.international-biopharma.com/sanofi-gsk-say-dual-acting-vaccine-prevents-covid-19-from-omicron-in-large-trial/ 2022-06-24T16:34:23+00:00 https://old.international-biopharma.com/radius-maker-of-bone-and-cancer-drugs-to-be-bought-in-take-private-deal/ 2022-06-24T16:33:25+00:00 https://old.international-biopharma.com/galapagos-with-latest-deals-charts-an-unexpected-journey-to-cell-therapy/ 2022-06-24T16:32:10+00:00 https://old.international-biopharma.com/uniqure-buoyed-by-early-data-for-huntingtons-gene-therapy/ 2022-06-24T16:30:36+00:00 https://old.international-biopharma.com/novartis-to-invest-250m-in-tropical-disease-drug-research/ 2022-06-24T16:29:48+00:00 https://old.international-biopharma.com/biogen-citing-insurance-challenges-shutters-one-of-its-aduhelm-studies/ 2022-06-24T16:28:51+00:00 https://old.international-biopharma.com/am-stabtest/ 2022-06-23T10:33:17+00:00 https://old.international-biopharma.com/roche-alzheimers-study-fails-in-another-setback-to-a-long-tested-hypothesis/ 2022-06-17T09:52:36+00:00 https://old.international-biopharma.com/fda-advisers-recommend-pfizer-moderna-covid-19-vaccines-for-youngest-children/ 2022-06-17T09:51:27+00:00 https://old.international-biopharma.com/pharma-under-the-microscope-as-ftc-considers-new-ways-to-review-acquisitions/ 2022-06-17T09:50:14+00:00 https://old.international-biopharma.com/with-biotech-in-retreat-third-rock-raises-1b-for-life-sciences-investing/ 2022-06-17T09:48:53+00:00 https://old.international-biopharma.com/alnylam-wins-fda-approval-of-rare-disease-drug-in-step-toward-profitability/ 2022-06-17T09:47:36+00:00 https://old.international-biopharma.com/boehringer-extends-cancer-dealmaking-with-right-to-buy-biotech-partner/ 2022-06-17T09:46:31+00:00 https://old.international-biopharma.com/pfizer-study-results-show-paxlovid-benefit-less-clear-in-lower-risk-patients/ 2022-06-17T09:45:33+00:00 https://old.international-biopharma.com/upstream-bio-a-richly-funded-startup-reveals-its-lead-drug-and-research-plans/ 2022-06-17T09:30:49+00:00 https://old.international-biopharma.com/gsk-wagers-2-1b-on-affinivax-and-its-next-generation-pneumonia-vaccine/ 2022-06-17T09:30:22+00:00 https://old.international-biopharma.com/regeneron-buys-control-of-cancer-drug-libtayo-from-sanofi/ 2022-06-17T09:29:58+00:00 https://old.international-biopharma.com/pfizer-to-exit-gsk-consumer-health-joint-venture-after-spinoff/ 2022-06-17T09:29:32+00:00 https://old.international-biopharma.com/former-editas-ceo-bosley-joins-uk-venture-capital-firm/ 2022-06-17T09:29:00+00:00 https://old.international-biopharma.com/scientists-home-in-on-cause-of-duchenne-gene-therapy-side-effect-2/ 2022-06-17T09:28:28+00:00 https://old.international-biopharma.com/lilly-to-expand-add-jobs-with-two-new-factories-in-indiana/ 2022-06-17T09:27:57+00:00 https://old.international-biopharma.com/adicet-data-hints-at-early-promise-for-gamma-delta-cell-therapy/ 2022-06-17T09:27:31+00:00 https://old.international-biopharma.com/merck-study-results-signal-blood-cancer-potential-for-new-type-of-immunotherapy/ 2022-06-17T09:27:07+00:00 https://old.international-biopharma.com/mirati-matches-amgen-with-updated-data-for-kras-blocking-cancer-drug/ 2022-06-17T09:26:31+00:00 https://old.international-biopharma.com/gerresheimer-partners-with-medtech-start-up-adamant-health-to-revolutionize-treatment-of-parkinsons-disease/ 2022-06-14T10:28:40+00:00 https://old.international-biopharma.com/forbion-raises-500m-to-back-growing-biotechs-amid-industry-slump/ 2022-06-13T08:17:02+00:00 https://old.international-biopharma.com/vertex-crispr-strengthen-case-for-pioneering-gene-editing-treatment/ 2022-06-13T08:14:50+00:00 https://old.international-biopharma.com/fda-panel-backs-bluebird-gene-therapy-despite-safety-risks/ 2022-06-13T08:12:21+00:00 https://old.international-biopharma.com/gsk-claims-first-positive-phase-3-result-for-an-rsv-vaccine/ 2022-06-13T08:10:26+00:00